How much cash does Utah Medical Products generate?

Utah Medical Products (UTMD) generated $13.3M in operating cash flow over the trailing twelve months.

What is Utah Medical Products's free cash flow?

After $317.0K of capital expenditures, Utah Medical Products's free cash flow was $13.0M over the trailing twelve months, down 4.5% year over year.

Where does Utah Medical Products's cash flow data come from?

Every line is extracted from Utah Medical Products's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Utah Medical Products UTMD Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$10.85M-16.3%	$11.29M-18.7%	$11.62M-23.8%	$12.55M-19.7%	$12.96M-20.9%
Depreciation and amortization	$837K+8.1%	$826K+13.2%	$814K+18.3%	$808K+26.3%	$774K+24.0%
Stock-based compensation	$411K+58.7%	$373K+45.7%	$334K+30.5%	$293K+14.5%	$259K+2.0%
Deferred income taxes	-$589K—	-$641K—	——	——	——
Impairment charges	——	——	——	——	——
Provision for credit losses	——	——	——	——	——
Change in inventories	-$90K+84.8%	-$1.2M-104%	-$1.09M—	-$1.05M—	-$591K—
Change in accounts payable	——	——	——	——	-$86K—
Change in accrued liabilities	——	——	——	-$2.25M-85.5%	-$1.69M-38.4%
Change in other assets	$120K+514%	$54K+68.8%	$34K+143%	-$68K+21.8%	-$29K—
Other working capital changes	-$918K—	-$0—	$2.49M—	$1.54M—	——
Amortization of intangible assets	$2.08M+0.9%	$2.13M+3.0%	$2.11M-12.7%	$2.09M-40.4%	$2.06M-55.3%
Non-cash operating lease expense	$59K+20.4%	$56K+9.8%	$54K+3.8%	$51K-3.8%	$49K-9.3%
Change in receivables	——	——	-$263K-186%	-$760K-356%	-$280K-231%
Net cash from operating activities	$13.34M-4.9%	$14.69M-0.9%	$14.15M-17.8%	$14.13M-23.6%	$14.02M-32.1%
Capital expenditures	$317K-19.1%	$371K+61.3%	$271K-12.9%	$333K-18.4%	$392K-36.6%
Acquired in-process research and development	$668K-4.8%	$668K-17.9%	$577K-31.2%	$582K-27.7%	$702K+2.8%
Net cash from investing activities	-$317K+20.2%	-$371K-78.4%	-$271K+6.2%	-$333K+13.7%	-$397K+32.8%
Dividends paid	$3.96M-5.6%	$3.98M-6.5%	$4.04M-5.8%	$4.11M-4.7%	$4.19M-2.6%
Repurchases of common stock	$5.26M-73.9%	$8.36M-58.2%	$14.07M+6.1%	$17.28M+84.0%	$20.2M+576%
Net cash from financing activities	-$9.22M+61.7%	-$12.34M+48.2%	-$18.11M-5.5%	-$21.39M-61.1%	-$24.09M-239%
Effect of exchange rate changes on cash	——	——	——	——	——
Net increase (decrease) in cash	$4.08M+139%	$2.78M+128%	-$4.19M-1,822%	-$7.04M-253%	-$10.48M-181%
Interest paid	$0—	$0—	$0—	$0—	$0—
Income taxes paid	$3.99M-12.9%	$4M-13.7%	$3.78M-25.2%	$4.17M-17.7%	$4.58M-4.7%
Amortization of capitalized software and acquired intangible assets	$2.08M+0.9%	$2.13M+3.0%	$2.11M-12.7%	$2.09M-40.4%	$2.06M-55.3%
Depreciation	$837K+8.1%	$826K+13.2%	$814K+18.3%	$808K+26.3%	$774K+24.0%
Increase (Decrease) in Accounts Receivable and Other Operating Assets	——	——	——	——	——
Increase (Decrease) in Deferred Income Taxes	——	-$659K-83.6%	-$584K-32.0%	-$509K+3.2%	-$434K+28.8%
Increase (Decrease) in Other Receivables	——	$5K+109%	-$9.75K+75.9%	-$24.5K+9.3%	-$39.25K-191%
Increase (Decrease) in Prepaid Expense and Other Assets	$120K+514%	$54K+68.8%	$34K+143%	-$68K+21.8%	-$29K—
Operating lease right-of-use asset amortization	$59K+20.4%	$56K+9.8%	$54K+3.8%	$51K-3.8%	$49K-9.3%
Accounts Receivable, Credit Loss Expense (Reversal)	——	——	——	——	——
Stock Option Plan Expense	$412K+59.1%	$374K+46.1%	$335K+30.9%	$293K+14.5%	$259K+2.0%
Cost of services	$15.79M-3.5%	$16.52M-1.4%	$16.57M-8.7%	$16.57M-13.3%	$16.36M-18.5%
Current Income Tax Expense (Benefit)	——	$3.44M—	$5.85M—	——	——
Earnings per common share - basic (in dollars per share)	$3.38-10.6%	$3.48-11.9%	$3.54-17.1%	$3.74-13.6%	$3.78-16.2%
Earnings per common share - diluted (in dollars per share)	$3.38-10.8%	$3.48-12.1%	$3.54-17.3%	$3.75-13.4%	$3.79-15.8%
Effective Income Tax Rate Reconciliation, Percent	——	41.9%—	40%—	——	——
General and administrative costs	——	$7.88M+0.6%	$7.87M-8.8%	$7.86M-16.6%	$7.85M-23.2%
Gross Profit	$21.75M-5.1%	$22M-8.9%	$22.06M-14.9%	$22.26M-19.0%	$22.92M-20.9%
Income before provision for income taxes	$13.43M-53.8%	$14.11M-53.0%	$27.81M-16.4%	$28.68M-15.4%	$29.05M-16.6%
Operating Income Loss	$10.81M-15.9%	$11.4M-16.1%	$11.89M-18.6%	$12.62M-17.1%	$12.86M-20.7%
Revenue From Contract With Customer Excluding Assessed Tax	$37.53M-4.4%	$38.52M-5.8%	$38.63M-12.4%	$38.83M-16.6%	$39.27M-19.9%
Royalty Income Nonoperating	——	$20K+33.3%	$18.75K+15.4%	$17.5K0.0%	$16.25K-13.3%
Sales and marketing	——	$2.05M+7.9%	$2.01M+9.0%	$1.98M+10.2%	$1.94M+11.5%
Selling General And Administrative Expense	——	——	——	——	——
Effect of dilutive RSUs and PSUs (in shares)	0—	0—	0-100%	0-100%	0-100%
Diluted (in shares)	12.9M-6.8%	13M-8.0%	13.3M-7.0%	13.5M-6.2%	13.8M-4.9%
Weighted average common shares outstanding, basic (in shares)	12.9M-6.8%	13M-8.0%	13.3M-7.0%	13.5M-6.0%	13.8M-4.7%
Foreign income taxes, net of refunds	——	——	——	——	——
Free cash flow	$13.02M-4.5%	$14.32M-1.9%	$13.88M-17.9%	$13.8M-23.7%	$13.63M-31.9%
Free cash flow	$13.02M-4.5%	$14.32M-1.9%	$13.88M-17.9%	$13.8M-23.7%	$13.63M-31.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Utah Medical Products.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Utah Medical Products generate?: Utah Medical Products (UTMD) generated $13.3M in operating cash flow over the trailing twelve months.
What is Utah Medical Products's free cash flow?: After $317.0K of capital expenditures, Utah Medical Products's free cash flow was $13.0M over the trailing twelve months, down 4.5% year over year.
Where does Utah Medical Products's cash flow data come from?: Every line is extracted from Utah Medical Products's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.